Research ArticlePQRI Special Section
Extractables Characterization for Five Materials of Construction Representative of Packaging Systems Used for Parenteral and Ophthalmic Drug Products
Dennis Jenke, James Castner, Thomas Egert, Tom Feinberg, Alan Hendricker, Christopher Houston, Desmond G. Hunt, Michael Lynch, Arthur Shaw, Kumudini Nicholas, Daniel L. Norwood, Diane Paskiet, Michael Ruberto, Edward J. Smith and Frank Holcomb
PDA Journal of Pharmaceutical Science and Technology September 2013, 67 (5) 448-511; DOI: https://doi.org/10.5731/pdajpst.2013.00933
Dennis Jenke
1Baxter Healthcare Corporation, Round Lake, IL, USA;
James Castner
2Pharma Interface Analysis, LLC, USA;
Thomas Egert
3Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim/Rhein, Germany;
Tom Feinberg
4Catalent Pharma Solutions, Morrisville, NC, USA;
Alan Hendricker
4Catalent Pharma Solutions, Morrisville, NC, USA;
Christopher Houston
5Bausch & Lomb, Rochester, NY, USA;
Desmond G. Hunt
6United States Pharmacopoeia, Rockville, MD, USA;
Michael Lynch
7Pfizer, Groton, CT, USA;
Arthur Shaw
7Pfizer, Groton, CT, USA;
Kumudini Nicholas
8Bureau of Pharmaceutical Sciences, Health Canada, Ottawa, ON, Canada;
Daniel L. Norwood
9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA;
Diane Paskiet
10West Pharmaceutical Services, Exton PA, USA;
Michael Ruberto
11Materials Needs Consulting LLC, Montvale, NJ, USA;
Edward J. Smith
12Packaging Science Resources, King of Prussia, PA, USA; and
Frank Holcomb
13United States Food and Drug Administration, Washington, DC, USA
References
- 1.↵
Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologics. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, May, 1999.
- 2.↵
Guideline on Plastic Immediate Packaging Materials. European Medicines Agency. CPMP/QWWP/4359/03. EMEA/CVMP/205/04. 5/19/05.
- 3.↵
Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry, Manufacturing, and Controls Documentation. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, October, 1998.
- 4.↵
Guidance for Industry. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products – Chemistry, Manufacturing and Controls Documentation. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, July, 2002.
- 5.↵
Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. PQRI Leachables and Extractables Working Group, September 9, 2006, available at http://www.pqri.org/pdfs/LE-Recommendations-to-FDA-09-29-06.pdf.
- 6.↵
Experimental Protocol for Qualitative Controlled Extraction Studies on Material Test Articles Representative of Prefilled Syringe (PFS) and Small Volume Parenteral (SVP) Container Closure Systems. PQRI Parenteral and Ophthalmic Drug Products Leachables and Extractables Working Group, December 9, 2009. Available at http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/Addl/PODP_Protocol_PhI.pdf.
- 7.↵
- Grob K.,
- Grob G.,
- Grob K.
- 8.↵
- Jenke D.
- 9.↵
Chapter 730 Plasma Spectrochemistry. In The United States Pharmacopeia, USP 34; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2010; pp 299–304.
- 10.↵
- Jenke D. R.
- 11.↵
- 12.↵
- 13.↵
- Arbin A.,
- Ostelius J.
- 14.↵
- 15.↵
- Arbin A.,
- Ostelius J.,
- Callmer K.,
- Sroka J.,
- Hanninen K.,
- Axelsson A.
- 16.↵
- 17.↵
- Srivastava S. P.,
- Saxena A. K.,
- Seth P. K.
- 18.↵
- Arbin A.,
- Jacobsson S.,
- Hanninen K.,
- Hagman A.,
- Ostelius J.
- 19.↵
- Snell R. P.
- 20.↵
- 21.↵
- Wright D. W.,
- Mahler K. O.,
- Davis J.
- 22.↵
- 23.↵
- Khaliq M. A.,
- Alam M. S.,
- Srivastava S. P.
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- 28.↵
- Hanawa T. E.,
- Muramatsu E.,
- Asakawa K.,
- Suzuki M.,
- Tanaka M.,
- Kawano K.,
- Seki T.,
- Juni K.,
- Kakajima S.
- 29.↵
- Loff S.,
- Subotic U.,
- Reinicke F.,
- Wischmann H.,
- Brade J.
- 30.↵
- Hill S. S.,
- Shaw B. R.,
- Wu A. H. B.
- 31.↵
- Loff S.,
- Kabs F.,
- Subotic U.,
- Schaible T.,
- Reinecke F.,
- Langbein M.
- 32.↵
- Nakamura Y.,
- Nakazawa K.,
- Ohmori S.,
- Kawano K.,
- Shin'ichirou N.,
- Kitada M.
- 33.↵
- Schoff H. W.,
- Rahman M.,
- Brazel C. S.
- 34.↵
- Wang Q.,
- Storm B. K.
- 35.↵
- Masucci P.,
- Moffat M. I.
- 36.↵
- McGuire G.,
- Falk K. G.
- 37.↵
- Wiener S.
- 38.↵
- 39.↵
- 40.↵
- 41.↵
- Reznek S.
- 42.↵
- Milosovich G,
- Mattocks A. M.
- 43.↵
- 44.↵
- Capper K. R.
- 45.↵
- 46.↵
- 47.↵
- Danielson J. W.,
- Oxborrow J. S.,
- Placencia A. M.
- 48.↵
- 49.↵
- Salmona G.,
- Assaf A.,
- Gayte-Sorbier A.,
- Airaudo C. B.
- 50.↵
- Jaehnke R. W. O.,
- Joerg R. G.
- 51.↵
- Jaehnke R.W.O.,
- Linde H.,
- Mosandl A.,
- Kreuter J.
- 52.↵
- Danielson J. W.
- 53.↵
- Norwood D. L.,
- Prime D.,
- Downey D. P,
- Creasey J.,
- Sethi S. K.,
- Haywood P.
- 54.↵
- Paskiet D. M.
- 55.↵
- 57.↵
- Xiao B.,
- Gozo S. K.,
- Herz L.
- 58.↵
- 59.↵
- Norwood D.,
- Ruberto M.,
- DeGrazio F.L.,
- Castner J.,
- Wong W.K.,
- Jenke D.
- 60.↵
- Sharma B.,
- Bader F.,
- Templeman T.,
- Lisi P.,
- Ryan M.,
- Heavner G. A.
- 61.↵
- Boven K.,
- Knight J.,
- Bader F.,
- Rossert J.,
- Eckardt K.,
- Casadevail N.
- 62.↵
- Pang J.,
- Blanc T.,
- Brown J.,
- Labrenz S.,
- Villalobos A.,
- Depaolis A.,
- Gunturi S.,
- Grossman S.,
- Lisi P.,
- Heavner G. A.
- 63.↵
- Jenke D. R.
- 64.↵
- Wong W. K.
- 65.↵
3.1.5. Polyethylene with Additives for Containers for Parenteral Preparations and for Ophthalmic Preparations. In the European Pharmacopoeia, 7th ed.; Council of Europe: Strasburg, France, 2010; pp 338–341.
- 66.↵
- 67.↵
- Goydan R.,
- Schwope A. D.,
- Reid R. C.,
- Cramer G.
- 68.↵
- 69.↵
- Azuma K.,
- Tanaka Y.,
- Tsundo H.,
- Hirata T.,
- Ishitani T.
- 70.↵
- Azuma K.,
- Tanaka Y.,
- Tsunoda H.,
- Ishitani T.,
- Tanaka Y.
- 71.↵
- Demertzis P.G.,
- Franz R.,
- Welle F.
- 72.↵
- Schwope A. D.,
- Till D. E.,
- Ehntholt D. J.,
- Sidman K. R.,
- Whelan R. H.,
- Schwartz P. S.,
- Reid R. C.
- 73.↵
- Helmroth I. E.,
- Bekhuis H. A. M.,
- Linssen J. P. H.,
- Dekker M.
- 74.↵
- Welle F.
- 75.↵
- Arias M.,
- Penichet I.,
- Ysambertt F.,
- Bauza R.,
- Zougagh M.,
- Rios A.
- 76.↵
- 77.↵
- Haishima Y.,
- Hayashi Y.,
- Yagami T.,
- Nakamura A.
- 78.↵
- 79.↵
- 80.↵
- 81.↵
- Chang C. M.,
- Chou C. C,
- Lee M. R.
- 82.↵
- Cao X.,
- Corriveau J.
- 83.↵
- Jakobs A.
- 84.↵
- Grimm M.
- 85.↵
- Shah D.,
- Cronin J.,
- Chacko M.,
- Gillum A.
- 86.↵
- Jenke D.,
- Odufu A.,
- Couch T.,
- Chacko M.,
- Strathmann S.,
- Edgcomb E.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 67, Issue 5
September/October 2013
Extractables Characterization for Five Materials of Construction Representative of Packaging Systems Used for Parenteral and Ophthalmic Drug Products
Dennis Jenke, James Castner, Thomas Egert, Tom Feinberg, Alan Hendricker, Christopher Houston, Desmond G. Hunt, Michael Lynch, Arthur Shaw, Kumudini Nicholas, Daniel L. Norwood, Diane Paskiet, Michael Ruberto, Edward J. Smith, Frank Holcomb
PDA Journal of Pharmaceutical Science and Technology Sep 2013, 67 (5) 448-511; DOI: 10.5731/pdajpst.2013.00933
Extractables Characterization for Five Materials of Construction Representative of Packaging Systems Used for Parenteral and Ophthalmic Drug Products
Dennis Jenke, James Castner, Thomas Egert, Tom Feinberg, Alan Hendricker, Christopher Houston, Desmond G. Hunt, Michael Lynch, Arthur Shaw, Kumudini Nicholas, Daniel L. Norwood, Diane Paskiet, Michael Ruberto, Edward J. Smith, Frank Holcomb
PDA Journal of Pharmaceutical Science and Technology Sep 2013, 67 (5) 448-511; DOI: 10.5731/pdajpst.2013.00933
Jump to section
Related Articles
- No related articles found.
Cited By...
- Science- and risk-based strategy to qualify prefillable autoclavable syringes as primary packaging material
- Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls)
- Principles for Management of Extractables and Leachables in Ophthalmic Drug Products
- Assessment of Extractable Elements from Elastomers
- Simulated Leaching (Migration) Study for a Model Container-Closure System Applicable to Parenteral and Ophthalmic Drug Products
- A Method Utilizing Ultra-High Performance Liquid Chromatography with Ultraviolet and Mass Spectrometric Detection for the Analysis of Material Extracts Produced during a Controlled Extraction Study